Table 2.

Association of HPV with clinicopathological features

		HPV negative	HPV positive	Univariant analysis			Multivariant analysis
				OR	95% confidence interval (CI)	P-value	OR	95% confidence interval (CI)	P-value
Perineural invasion	Yes	27 (29)	2 (28.6)	1.28	(0.26–6.43)	0.762	1.65	(0.26–10.64)	0.596
	No	50 (53.8)	4 (57.1)
	unknown	16 (17.2)	1 (14.3)
Lymphovasc ular invasion	Yes	34 (36.6)	3 (42.9)	1.33	(0.24–7.32)	0.74	1.68	(0.21–13.24)	0.621
	No	47 (50.5)	3 (42.9)
	unknown	12 (13.9)	1 (14.3)
Surgical margin involvement	Yes	8 (8.6)	0 (0)	1	(0.099–10.51)	1	0.81	(0.04–17.45)	0.891
	No	80 (86)	6 (85.7)
	unknown	5 (5.4)	1 (14.3)
Lymph node involvement	Yes	50 (53.8)	3 (42.9)	0.48	(0.1–2.28)	0.354	0.52	(0.09–2.58)	045
	No	33 (35.5)	4 (57.1)
	unknown	10 (10.8)	0 (0)
ER expression	No	25 (26.9)	0 (0)	3.35	(0.32–34.66)	0.309	3.01	(0.25–37.02)	0.387
	Yes	57 (61.3)	6 (85.7)
	unknown	11 (11.8)	1 (14.3)
PR expression	No	30 (32.3)	3 (42.9)	0.90	(0.19–4.26)	0.891	1.10	(0.13–9.21)	0.927
	Yes	51 (54.8)	4 (57.1)
	unknown	12 (12.9)	0 (0)
Ki-67 expression	No	23 (24.7)	2 (28.6)	0.97	(0.18–5.34)	0.972	0.71	(0.10–5.14)	0.736
	Yes	61 (65.6)	5 (71.4)
	unknown	9 (9.7)	0 (0)
Tumor grade	well-differentiated	23 (24.7)	0 (0)	1.84	(0.67–5.07)	0.238	1.80	(0.58–5.58)	0.311
	moderately-differentiated	47 (50.5)	5 (71.4)
	poorly-differentiated	20 (21.5)	2 (28.6)
	unknown	3 (3.2)	0 (0)
HER2 expression	No	53 (57)	5 (71.4)	0.62	(0.12–3.32)	0.577	0.57	(0.09–3.49)	0.573
	Equivocal	15 (16.1)	1 (14.3)
	Yes	13 (14)	1 (14.3)
	unknown	12 (12.9)	0 (0)